AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05634863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Doppler probe manufactured by COOK Medical Company.
Description: The continuous audible Doppler signals produced by the monitoring device represent the blood flowing in the renal artery. This is an indicator of graft perfusion. Cessation of audible Doppler signals is the key that may suggest hampered blood flow due to vascular complications. In the intervention group, the monitoring device will be used as an added mechanism to monitor graft perfusion.
Study NCT06419140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
Description: Motivational counseling to perform nutritional, psychological, and exercise inventions
Study NCT06417619 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Psychoeducation
Description: The Effect of Mindfulness-Based Psychoeducation on Depression Level of Depression Patients
Study NCT05543473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Therapy
Description: an exercise-based treatment program designed to promote vestibular adaptation and substitution. The goals of VRT are to enhance gaze stability, to enhance postural stability, to improve vertigo, and to improve activities of daily living. VRT facilitates vestibular recovery mechanisms: vestibular adaptation, substitution by the other eye-movement systems, substitution by vision, somatosensory cues, other postural strategies, and habituation
Study NCT04732286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered intravenously at a dose of 1200 mg on Day 1 of each 21-day cycle.
Study NCT04732286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT06107075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: 40g bio-active whey protein concentrate powder containing phospholipids
Study NCT06107075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: around 40g pea protein powder not containing phospholipids
Study NCT05701332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette Guerin
Description: effect of local B.C.G and Gemcitabine on semen parametes and testicular volume
Study NCT06194396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: chlorhexidine will be used as skin disinfectant before insertion of CVC, PICC line, and umbilical catheter
Study NCT06194396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol
Description: alcohol will be used as skin disinfectant before insertion of CVC ,PICC line and umbilical catheter
Study NCT05820425 — intervention group
Intervention type: OTHER
Intervention: LFP and EEG recording
Description: STN LFP and EEG recording during the OFF and ON medication condition
Study NCT05422508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Suduvax
Description: 0.5ml, single dose, subcutaneous injection
Study NCT04789486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX
Description: Injected gadolinium-based nanoparticles
Study NCT04789486 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Stereotactic magnetic resonance-guided adaptive radiation therapy
Study NCT03967548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.004%
Study NCT05537805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided transcervical fallopian tube catheterization during hysterosalpingo-foam sonography in the treatment of proximal tubal obstruction
Description: The intervention included the usage of the modified cornual cannulation set (COOK) which was inserted through cervical canal to uterine cavity, followed by fallopian tube irrigation with contrast foam (Ex-EM) during hysterosalpingo-foam sonography under ultrasonographic imaging.
Study NCT05199259 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-analyte Blood Test
Description: A clinical diagnostic test based upon the detection and quantification of DNA methylation markers in cell-free DNA (cfDNA) isolated from plasma and of tumor-specific proteins isolated from serum.
Study NCT06057363 — intervention group
Intervention type: OTHER
Intervention: volumetric evaluation of gingival augmentation around dental implants
Description: objective volumetric and clinical assesment of vestibular gingival soft tissues changes upon treatment with laser-aided pouch roll augmentation technique and implant placement over a 12-month follow-up
Study NCT04986800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROACTIVE Parent
Description: PROACTIVE Parent will educate parents about their child's mental health symptoms and treatment, how to talk to the child's therapist to support treatment goals at home and in the community. PROACTIVE Parent will teach parents the function of child behavior, the role of symptomatology in child behaviors, and strategies to promote effective behavior management and healthy coping. Parents will also learn skills to manage their own emotional dysregulation to promote calm parental responding and promote healthy parent-child interaction and communication.
Study NCT06196086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography examination
Description: Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.
Study NCT05506059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Participants will have ultrasounds of the heart by two different emergency medicine doctors.
Study NCT05506059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Participants will have ultrasounds of the heart by two different emergency medicine doctors.
Study NCT06501664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal irinotecan
Description: Liposomal irinotecan 70 mg/m²
Study NCT06501664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h
Study NCT06501664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m² bolus then 2400 mg/m2 over 46 h
Study NCT06501664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LV
Description: LV 400 mg/m²
Study NCT06501664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV
Description: LV 400 mg/m²
Study NCT06501664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m²
Study NCT06499987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection anastomosis
Description: resection of stenotic part of trachea and reanastmosis
Study NCT04890210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early Diet Group
Description: Initiation of clear fluid diet 1 hour after esophageal variceal ligation
Study NCT04890210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Late Diet Group
Description: Initiation of clear fluid diet 6 hours after esophageal variceal ligation
Study NCT05586633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep paravertebral periforaminal ozone injeciton
Description: Deep paravertebral periforaminal ozone injection was administered to the patients in the ozone injection group 4 times under ultrasound guidance, 10 ug/ml 5ml twice a week in the first week and 15 ug/ml 5ml twice a week in the second week.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up.
Study NCT05586633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal steroid injeciton
Description: Transforaminal epidural steroid injection group, steroid (dexamethasone 8mg/2ml 2ml) injection was performed under the guidance of fluoroscopy.~Patients will be evaluated according to the study criteria at the beginning, at 15 days, 1 month, and 2 months. Physical examination findings were evaluated before starting the treatment and at the 2nd month follow-up.
Study NCT05713097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TSI
Description: TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician).
Study NCT05309863 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle management
Description: Increasing the level of physical activity, dietary intervention, acquiring healthy eating habits, and psychological support.
Study NCT05154292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serious Game: Emotional Health Island (SAEM)
Description: This intervention aims to aim to develop competencies for emotional regulation through exposure and acceptance strategies. This intervention is applied through a serious game developed for this purpose. the adolescent will complete a series of missions aimed at developing skills related to psychological flexibility, namely, greater psychological acceptance, mindfulness in the present moment, and committed actions in the direction of personal values. This serious game is guided by a therapist.
Study NCT06222151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1: Mobilization during hospitalization
Description: Surgical ICU Optimal Mobilization Score (SOMS) will be used to initiate early mobilization. SOMS consists of five levels of mobilization reaching from no activity to ambulation. Thirty minutes after PACU-arrival, the patient will be asked to do lower leg exercises. If this is possible, the patient will advance to the next level of mobilization. If not possible, level zero is recorded and the patient rests for another 30 minutes before attempting level one again. This continues until the patient succeeds with level four. Safety criteria for advancing to the next level of mobilization are based on criteria for mobilizing patients in the ICU. The intervention group will receive standard care with additional supervised mobilization while hospitalized. This mobilization consist of walking 1000 steps on postoperative day (POD) 0 and 500 steps on POD1 before discharge. Step counts are measured using pedometers.
Study NCT06222151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 1: Mobilization during hospitalization
Description: Surgical ICU Optimal Mobilization Score (SOMS) will be used to initiate early mobilization. SOMS consists of five levels of mobilization reaching from no activity to ambulation. Thirty minutes after PACU-arrival, the patient will be asked to do lower leg exercises. If this is possible, the patient will advance to the next level of mobilization. If not possible, level zero is recorded and the patient rests for another 30 minutes before attempting level one again. This continues until the patient succeeds with level four. Safety criteria for advancing to the next level of mobilization are based on criteria for mobilizing patients in the ICU. The intervention group will receive standard care with additional supervised mobilization while hospitalized. This mobilization consist of walking 1000 steps on postoperative day (POD) 0 and 500 steps on POD1 before discharge. Step counts are measured using pedometers.
Study NCT06222151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 2: Mobilization the first 4 postoperative weeks
Description: Intervention 2 will start the first weekday after discharge and continue for 4 weeks. Four supervised physical activity sessions and 8 sessions using telerehabilitation. The activities are low-intensity exercises (walking and lightly strength training using resistance bands) with progressed intensity throughout the weeks. The exercises will be individually progressed to meet the participant's level of activity, as it is important the participants benefit as much as possible from the intervention. The participants will receive information about different possibilities for leisure activities, for motivation to continue physical activity after the first 4 weeks.
Study NCT06222151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention 2: Mobilization the first 4 postoperative weeks
Description: Intervention 2 will start the first weekday after discharge and continue for 4 weeks. Four supervised physical activity sessions and 8 sessions using telerehabilitation. The activities are low-intensity exercises (walking and lightly strength training using resistance bands) with progressed intensity throughout the weeks. The exercises will be individually progressed to meet the participant's level of activity, as it is important the participants benefit as much as possible from the intervention. The participants will receive information about different possibilities for leisure activities, for motivation to continue physical activity after the first 4 weeks.
Study NCT06222151 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group receives standard care.~Patients are mobilized to sit at the bedside before being transferred to the surgical ward. However, it is not used as prophylactic pain management nor is there a structured evidence based protocol with regard to mobilization. The control group will also be equipped with pedometers. They are encouraged to mobilize, and they receive a form in which they can write down mobilization for each hour. There is no planned supervised mobilization. As patients in the control group are assigned to standard care, they will not receive any supervised physical activity after discharge.
Study NCT06222151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group receives standard care.~Patients are mobilized to sit at the bedside before being transferred to the surgical ward. However, it is not used as prophylactic pain management nor is there a structured evidence based protocol with regard to mobilization. The control group will also be equipped with pedometers. They are encouraged to mobilize, and they receive a form in which they can write down mobilization for each hour. There is no planned supervised mobilization. As patients in the control group are assigned to standard care, they will not receive any supervised physical activity after discharge.
Study NCT05626530 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letermovir
Description: Open label 480 mg given daily for 60 days
Study NCT04899297 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: All parents of patients visited at an outpatient service dedicated to the treatment of vertebral deformities will be recruited at the end of the medical clinical evaluation. The doctor will invite all subjects to complete the questionnaire anonymously at the end of each follow-up visit.
Study NCT03670875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave inulin
Description: Will be provided in dehydrated apple cubes
Study NCT03670875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Will be provided in capsules
Study NCT03670875 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: O3FA
Description: Will be provided in capsules
Study NCT03670875 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
Study NCT05196659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated comprehensive cardiovascular disease management
Description: 1. Electronic Health Record-Decision Support Software (EHR-DSS):~   * Electronic patient health record storage~  * Management prompts to the clinical team (following algorithms)~  * Structured follow-up schedule with automatic reminders to patients, clinical team, and non-physician health worker~2. Non-physician health worker-led continuity of care:~   - individually tailored follow-up and guidance regarding treatment adherence as well as help in resolving issues related to access, convenience, cost of care, and equity~3. Text-message based reminders for a healthy lifestyle~4. Patient diary containing visual assessment tool for adherence to medication (VITA) and reinforcement tool for lifestyle modification~5. Quarterly audit and feedback to the clinical team
Study NCT05438316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril tablet 10 mg
Description: Ramipril is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of ramipril.
Study NCT05438316 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tritace® tablet 10 mg
Description: Tritace® is manufactured by Sanofi-Aventis Deutschland GmbH, Germany. Each tablet contains 10 mg of ramipril.
Study NCT04740047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ion Endoluminal System
Description: Robotic bronchoscopy with c-arm imaging.
Study NCT04582578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT
Description: The experimental group will be treated with CRT in addition to optimal medical therapy for HF. In addition, the trial will further compare two methods of delivering CRT. One experimental group will receive BiV-CRT, while the second experimental group will receive CS-CRT
Study NCT06320483 — intervention group
Intervention type: DEVICE
Intervention: Vibroacoustic device BARK VibroLUNG
Description: The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.~The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.~Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.~The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the lung opening maneuver.
Study NCT06281483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: Under aseptic conditions, 20 mL of whole blood will be withdrawn from each patient and will be collected in the centrifuge tube prefilled with Anticoagulant Citrate Dextrose (1.5 mL each). A two-stage centrifugation process (double-spin method) will be employed for the preparation of PRP. The first spin is at 100 relative centrifugal force (RCF) (g) for 10 min, while the second spin is at 400 RCF for 10 min. PRP will be injected into the base of the ulcer and the surrounding skin. Group A: will receive treatment that will include PRP application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
Study NCT06281483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich fibrin
Description: 20 ml blood will be drawn from each patient by venipuncture under aseptic precautions in four sterile glass tubes of 5-ml capacity without anticoagulant and immediately centrifuged. A single stage centrifugation process, that is (200 g for 8 min), has been found to produce a fibrin clot with the highest platelet and WBC count and highest overall cumulative growth factor yield. Group B: will receive treatment that will include PRF application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.
Study NCT06281483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical debridement, normal saline washing and dressing coverage
Description: Each patient will receive the same conventional debridement and dressing coverage (After opening the bandage, the ulcer will be irrigated with normal saline and will be prepared for debridement as required to remove dead tissues and hyperkeratotic skin. Then, a second wash with normal saline will be done to remove any debris), but without any PRP nor PRF application.
Study NCT06501755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
Study NCT06501755 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
Study NCT05294094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended learning
Description: The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.